0
Corrections |

Omissions in Acknowledgments in: The Treatment for Adolescents With Depression Study (TADS): Long-term Effectiveness and Safety Outcomes FREE

Arch Gen Psychiatry. 2008;65(1):101. doi:10.1001/archgenpsychiatry.2007.22.
Text Size: A A A
Published online

Omissions in Acknowledgments. In the Original Article by The TADS Team titled “The Treatment for Adolescents With Depression Study (TADS): Long-term Effectiveness and Safety Outcomes,” published in the October issue of the Archives (2007;64[10]:1132-1144), omissions occurred in the Financial Disclosure portion of the Acknowledgments on page 1142. The Financial Disclosure should have read as follows: “Dr Albano has received research support from Wyeth-Ayerst Pharmaceuticals, has been a consultant to Wyeth-Ayerst Pharmaceuticals and Pfizer Inc, has received an honorarium from Pfizer Inc, and has received royalties from Oxford University Press. Dr Casat has received research support from Eli Lilly and Company, GlaxoSmithKline, Shire, Bristol-Myers Squibb Company, AstraZeneca, Sanofi-Synthelabo, Pfizer Inc, and Ortho-McNeil Inc and has served on the advisory board and the speaker's bureau for Eli Lilly and Company and GlaxoSmithKline. Dr Emslie has received research funding from Eli Lilly and Company, Organon, RepliGen Corporation, Forest Laboratories Inc, Wyeth-Ayerst Pharmaceuticals, Novartis, and SmithKline Beecham; has been a consultant to Eli Lilly and Company, GlaxoSmithKline, Forest Laboratories Inc, Wyeth-Ayerst, and Pfizer Inc; and has served on the speaker's bureau for Ortho-McNeil Inc. Dr Fairbank has been a consultant to RTI International and Copernicus Group. Dr Findling has received research support from, has been a consultant to, and/or has served on the speaker's bureau for Abbott Laboratories, AstraZeneca, Best Practices, Bristol-Myers Squibb Company, Celltech-Medeva, Forest Laboratories Inc, GlaxoSmithKline, Johnson & Johnson, Layton BioSciences Inc, Eli Lilly and Company, Nature's Herbs, New River Pharmaceuticals Inc, Noven Pharmaceuticals Inc, Novartis, Organon, Otsuka America Inc, Pfizer Inc, Sanofi-Aventis, Shire, Solvay, Somerset Pharmaceuticals Inc, and Wyeth. Dr Ginsburg has received research support from Pfizer Inc. Dr Grimm has received research support from GlaxoSmithKline, Sepracor Inc, Shire, Ortho-McNeil Inc, AstraZeneca, Organon, Forest Laboratories Inc, Cephalon Inc, Jazz Pharmaceuticals Inc, Sanofi-Aventis, Merck & Co Inc, Eli Lilly and Company, ALZA Corporation, Johnson & Johnson, and New River Pharmaceuticals Inc. Dr Leventhal has been a consultant to Janssen, Eli Lilly and Company, and the National Institutes of Health (NIH); has served on the speaker's bureau for Bristol-Myers Squibb Company and Cephalon Inc; and has received research funding from NIH, Eli Lilly and Company, Shire, Forest Laboratories Inc, Otsuka America Inc, and Novartis. Dr Kastelic has received an honorarium from Pfizer Inc. Dr Kratochvil has been a consultant or scientific advisor to Eli Lilly and Company, Shire, Cephalon Inc, Organon, AstraZeneca, Boehringer-Ingelheim, Abbott Laboratories, and Pfizer Inc; has received research support from Abbott Laboratories, Cephalon Inc, Eli Lilly and Company, Forest Laboratories Inc, GlaxoSmithKline, and Ortho-McNeil Inc; has served on the speaker's bureau for Eli Lilly and Company; and has received study drug for an NIMH-funded study from Eli Lilly and Company. Dr March has been a consultant or scientific advisor to Pfizer Inc, Eli Lilly and Company, Wyeth, GlaxoSmithKline, Jazz Pharmaceuticals Inc, and MedAvante; has held stock in MedAvante; has received research support from Eli Lilly and Company and study drug for an NIMH-funded study from Eli Lilly and Company and Pfizer Inc; and is the author of the Multidimensional Anxiety Scale for Children. Dr Pathak has received research support from Forest Laboratories Inc. Dr Posner has received research support from GlaxoSmithKline, Forest Laboratories Inc, Eisai Inc, AstraZeneca, Johnson & Johnson, Abbott Laboratories, Wyeth Research, Organon USA, Bristol-Meyers Squibb Company, Sanofi-Aventis, Cephalon Inc, Novartis, Shire Pharmaceuticals, and UCB Pharma as part of an effort to help execute the US Food and Drug Administration adult suicidality classification mandates. Dr Silva has been a consultant to Pfizer Inc. Dr Walkup has received research support from Eli Lilly and Company, Pfizer Inc, and Abbott Laboratories; has been a consultant to Eli Lilly and Company, Pfizer Inc, Jazz Pharmaceuticals Inc, and Cephalon Inc; and has received honoraria from Eli Lilly and Company and Pfizer Inc. Dr Waslick has received research support from Eli Lilly and Company and Johnson & Johnson. Dr Weller has been a consultant to and/or received research support from Otsuka America Inc, AstraZeneca, Pharma Starr, Shire, Jazz Pharmaceuticals Inc, GlaxoSmithKline, Eli Lilly and Company, Johnson & Johnson, and Organon.”

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.